Also found in: Wikipedia.
PROMETAProtection del Medio Ambiente Tarija
References in periodicals archive ?
Participants opted for the PROMETA Treatment Program for a variety of reasons: to improve their quality of life, to maintain abstinence, or to prevent incarceration due to noncompliance with drug court requirements.
All participants signed a "consent-for-treatment" document describing the PROMETA Treatment Program.
The effectiveness of the PROMETA Treatment Program was measured by the following observations:
That initial analysis was based on results from a three-month period starting when the first enrolled participant commenced the PROMETA Treatment Program (March 20, 2006, to June 16, 2006).
Only three of the 40 original participants did not complete the medical portion of the PROMETA Treatment Program.
The most salient result of the PROMETA Treatment Program is participants' reporting of the almost total elimination of cravings for their drug of choice, compared with very high levels of cravings witnessed at the start of the pilot.
Peer-review publication brings additional validation to the PROMETA Treatment Program, and results from the alcohol studies are providing greater clarity for clinicians as to when use of the PROMETA Treatment Program in alcohol dependent patients may be beneficial.
Volpicelli's study was much larger, involving 117 lower-CIWA subjects, and it demonstrated that the PROMETA group had better clinical outcomes and achieved statistical significance during the active treatment period among subjects with a history of alcohol withdrawal symptoms.
Although not statistically significant, results also favored higher-CIWA PROMETA subjects, as compared to placebo, in percent days abstinent, craving, percent heavy drinking days, and drinks per day.
The 14-week study, over a 6 week treatment phase and an 8 week follow up phase, was designed to evaluate the impact of PROMETA on percent days abstinent, other use measures and cravings.
Anton's study, PROMETA had no effect or a lesser response compared to placebo subjects, who fared better in the study.
Alcohol craving as measured by the Penn Alcohol Craving Scale was significantly reduced in the PROMETA group, by 39% from pre-infusion status to end of the active treatment phase compared to a 14% decrease in the placebo group (p=0.